Welcome to our dedicated page for Agentix SEC filings (Ticker: AGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Agentix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Agentix's regulatory disclosures and financial reporting.
Agentix Corp. reported another loss in its quarter ended December 31, 2025, with net loss of $78,595 for the quarter and $408,526 for the nine months, on no revenue. Cash was only $6,396 against current liabilities of $3,504,396, and accumulated deficit reached $6,930,054, leading management to state there is substantial doubt about the company’s ability to continue as a going concern. Operations are being funded largely through related-party payables and a secured note from Gray’s Peak, and disclosure controls and procedures were deemed not effective as of December 31, 2025.
Agentix Corp. (AGTX), a clinical-stage biotech focused on metabolic diseases, reported no revenue for the three and six months ended September 30, 2025 and remains pre-commercial. The company posted a net loss of $144,107 for the quarter and $329,931 for the six-month period, compared with losses of $90,669 and $241,386 a year earlier, as higher professional and research and development costs and rising interest expense outweighed tight general and administrative spending.
Agentix ended the period with just $5,601 in cash and total current liabilities of $3,423,639, including significant related-party payables and a related-party note payable of $343,350. The accumulated deficit reached $6,851,459, and management concludes these conditions raise substantial doubt about the company’s ability to continue as a going concern without new financing. Common shares outstanding were 40,066,951 as of September 30, 2025.